Advancing clinical R&D, real-world evidence, and patient outcomes with digital biomarkers and software-based therapeutics

Our Approach

Access new avenues of care and bring evidence-based digital medicine to the patients who need it.

Using one of the only FDA-cleared algorithms, Biofourmis accelerates pharmaceutical product innovation and clinical research with a holistic, end-to-end solution to help improve patient outcomes.

Trusted by leading biopharma companies, payers, and patients.

Digital Therapeutics

Pioneering a new category of medicine

We partner with leading biopharmaceutical companies in the development of clinically-validated, software-based therapeutics that treat and manage patients with unmet clinical needs.

  • Patient-centric solutions with disease-specific journeys, notifications, vitals, and validated questionnaires and outcomes
  • Streamlined data collection through wearable biosensors and connected devices, integrated with our proprietary Biovitals platform
  • End-to-end digital therapeutic development and lifecycle management – from strategy and value proposition, through development and validation, to commercial deployment and product evolution

Digital Biomarkers

Delivering data to personalize treatment

Utilize continuous biometric data and machine learning algorithms to gain objective clinical measures and generate new insights into the status of the patient. Incorporating these biomarkers into clinical development enable the personalization of drug discovery and individualization of clinical care.

  • 50+ in-house data scientists to customize development of proprietary algorithms to support new novel digital biomarkers

  • Gain longitudinal insights into disease progression for an individual patient, or for a collective population

  • User-friendly interface to reduce site burden and increase satisfaction for healthcare professionals

Medication adherence

Empowering patient engagement

Our digital patient engagement solutions simplify personalized clinical care plans for patients, with individual daily activities, reminders, questionnaires, and user-friendly access to care teams through integrated 24/7 communication via text, talk, or video.

  • Optimize medication adherence with patient-friendly applications
  • Power stronger discussions with health authorities, payers, and providers with increased evidence of value-based outcomes and comparative effectiveness
  • Provide compelling new value-based messaging for greater differentiation and extended life of marketing-authorized products

Partner Case Studies

Digital Medicine with Chugai Pharmaceutical CO., LTD

Chugai is objectively assessing pain associated with endometriosis to better understand its pathology and treatment.

Decentralized Clinical Trials with the University of Hong Kong

The University of Hong Kong is using the Biovitals Index to remotely monitor and identify COVID-19-related physiological biomarkers that indicate deterioration in patients.

Commercialization with Novartis

Novartis is partnering with Biofourmis to monitor heart failure patients who are taking Novartis’ drug to reduce hospital readmissions and emergency room visits.

What our partners are saying

“Through the partnership with Biofourmis, a leading company in research, development, and commercialization of digital medicine, Chugai will set out to objectively assess pain associated with endometriosis and better understand its pathology.”

Satoko Shisai, Chugai’s Vice President, Head of Digital & IT Supervisory Division

Biofourmis Digital Medicine Pipeline

Our digital medicine portfolio covers a range of patient conditions, including heart failure, acute coronary syndrome, COPD, oncology, and chronic pain.

Access The Whitepaper

Accelerating Biopharmaceutical Innovation with Digital Therapeutics to Improve Patients' Quality of Life

Learn more about how you can accelerate innovation with digital therapeutics to improve patient outcomes.

Deliver better patient outcomes with Biofourmis digital medicine